213 search results for: Pathophysiology
Immunological Drivers in CSU: Diverse Pathways to Mast Cell Activation
In this video from EADV 2025, Dr. Hawkes reviews the pathophysioogy of CSU with a focus on the role of type 2 inflammation
KOL Video Interview – Dr Amy Paller
In this exclusive video interview, Dr Amy Paller discusses two topics: 1) The importance of CCL17 (TARC) as a biomarker in pediatric patients with AD, and 2) How IL-4 and IL-13 contribute to skin barrier dysfunction in AD.
Lung Function Decline: Why it Matters and What’s at Stake for Patients
Understand the drivers of lung function decline in chronic obstructive pulmonary disease (COPD), including chronic inflammation, key risk factors, and the impact on patient well-being .
Expert Interview: Inflammatory Cell Infiltrate and Type 2 Inflammation in PN and CSU
Dr. Metz describes the inflammatory cell infiltrate seen in PN and CSU and how inflammatory cells in the skin contribute to a type 2 inflammatory environment.
Connecting the Dots: Novel Insights on Type 2 Cytokines Mediating Neuroimmune Dysregulation in PN and CSU
Dr. Kim discusses the roles of type 2 cytokines at the neuroimmune axis in PN and CSU and conveys how neuroimmune interactions give rise to chronic itch and skin lesions in each disease
What Could Remission Mean in AD?
Dr. Simpson explores the concept of remission in AD, focusing on minimal disease activity and long-term remission, discussing how disease modification in AD can impact the course of the disease and its associated comorbidities.
Neuroiflammation and Neurogenic Itch in Prurigo Nodularis
Dr. Chovatiya discusses the neuroinflammatory mechanisms of PN.
Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation
Examine underlying type 2 inflammation as a driver of airway hyperresponsiveness in patients with asthma.
Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis
Learn more about how chronic and systemic type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis
Can advanced systemic therapies modify pathomechanisms in AD?
Dr. Ramien discusses evidence showing that advanced therapies can modify the mechanisms of atopic dermatitis, improving skin barrier function, normalizing the skin microbiome, and reducing chronic itch.
Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?
Dr. Amy Paller discusses how targeting IL-4 and IL-13 can improve burden of AD.
Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD
This video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia features Dr. Lisa Weibel presenting how local type 2 inflammation within the skin contributes to epidermal barrier dysfunction, dysbiosis, and neuroimmune dysfunction, leading to the clinical signs and symptoms of AD. Dr. Weibel also reviews how systemic inflammation affects organ systems beyond the skin, and could potentially manifest as atopic and non-atopic comorbidities.
